Concordia Healthcare Corp. (NASDAQ:CXRX) shares shot up 4% during trading on Thursday . The stock traded as high as $20.86 and last traded at $20.86, with a volume of 152,954 shares trading hands. The stock had previously closed at $20.06.

Several brokerages recently commented on CXRX. Canaccord Genuity reissued a “buy” rating on shares of Concordia Healthcare Corp. in a research report on Saturday, April 23rd. TD Securities reissued a “buy” rating and set a $45.00 price target (down from $48.00) on shares of Concordia Healthcare Corp. in a research report on Thursday, March 31st. Royal Bank Of Canada reissued an “outperform” rating and set a $74.00 price target (down from $75.00) on shares of Concordia Healthcare Corp. in a research report on Tuesday, May 17th. Finally, Zacks Investment Research raised Concordia Healthcare Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $52.35.

The stock’s market cap is $1.07 billion. The firm has a 50-day moving average price of $24.89 and a 200 day moving average price of $28.44.

Concordia Healthcare Corp. (NASDAQ:CXRX) last issued its earnings results on Friday, May 13th. The company reported $1.35 EPS for the quarter, missing analysts’ consensus estimates of $1.54 by $0.19. The company earned $228.50 million during the quarter, compared to analyst estimates of $231 million. Concordia Healthcare Corp.’s revenue for the quarter was up 570.1% compared to the same quarter last year. Equities research analysts expect that Concordia Healthcare Corp. will post $6.17 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Friday, July 15th will be paid a $0.075 dividend. The ex-dividend date is Wednesday, July 13th. This represents a $0.30 dividend on an annualized basis and a dividend yield of 1.44%.

Other institutional investors have made changes to their positions in the company. Swiss National Bank increased its position in shares of Concordia Healthcare Corp. by 26.7% in the fourth quarter. Swiss National Bank now owns 49,810 shares of the company’s stock worth $2,031,000 after buying an additional 10,510 shares during the last quarter. Thornburg Investment Management Inc. increased its position in shares of Concordia Healthcare Corp. by 48.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 116,235 shares of the company’s stock worth $4,746,000 after buying an additional 37,847 shares during the last quarter. Morgan Stanley increased its position in shares of Concordia Healthcare Corp. by 24.6% in the fourth quarter. Morgan Stanley now owns 269,768 shares of the company’s stock worth $11,015,000 after buying an additional 53,305 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Concordia Healthcare Corp. during the fourth quarter worth $2,419,000. Finally, ProShare Advisors LLC acquired a new position in shares of Concordia Healthcare Corp. during the fourth quarter worth $1,671,000.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc, which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.